Filippo Gagliardi
Overview
Explore the profile of Filippo Gagliardi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
94
Citations
600
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
De Domenico P, Gagliardi F, Roncelli F, Snider S, Mortini P
J Neurooncol
. 2025 Mar;
PMID: 40080248
Background: Glioblastoma (GBM) demonstrates extensive immunomodulatory mechanisms that challenge effective therapeutic interventions. These phenomena extend well beyond the tumor microenvironment (TME) and are reflected in the circulating immunophenotype. B lymphocytes...
2.
Gagliardi F, De Domenico P, Snider S, Roncelli F, Comai S, Mortini P
Crit Rev Oncol Hematol
. 2025 Feb;
209:104657.
PMID: 39986404
Background: Glioblastoma (GBM) is the most aggressive primary brain tumor exhibiting extensive immune evasion mechanisms that hinder effective therapeutic interventions. This narrative review explores the immunomodulatory pathways contributing to tumor...
3.
Snider S, Gagliardi F, De Domenico P, Comai S, Bertazzo A, Nasini S, et al.
Int J Tryptophan Res
. 2025 Feb;
18:11786469241312475.
PMID: 39959303
Background: In recent years, there has been a growing interest in exploring the potential contribution of tryptophan (TRP) metabolism via the kynurenine (KP) and serotonin (SP) pathways in Glioblastoma (GBM)...
4.
Snider S, De Domenico P, Roncelli F, Bisoglio A, Braga M, Ghelfi A, et al.
Oncol Lett
. 2024 Oct;
28(6):576.
PMID: 39397801
Glioblastoma (GBM) is the most common, fast-growing, and aggressive malignant primary CNS tumor, with a survival time of ~15 months despite the use of surgery and adjuvant treatments. In recent...
5.
Gagliardi F, De Domenico P, Snider S, Calcagnile R, Roncelli F, Barzaghi L, et al.
Crit Rev Oncol Hematol
. 2024 Oct;
204:104526.
PMID: 39370060
This is a single-center experience and metanalysis of the safety and efficacy measures of Gamma-knife stereotactic radiosurgery (SRS-GK) for radiation-induced meningiomas (RIMs). This study comprised a single-center analysis of SRS-GK...
6.
Azzimonti M, Esposito F, Poliani P, Gagliardi F, Anzalone N, Panni P, et al.
Neurology
. 2024 Jul;
103(3):e209644.
PMID: 38981088
No abstract available.
7.
Calimeri T, Anzalone N, Cangi M, Fiore P, Gagliardi F, Miserocchi E, et al.
Lancet Haematol
. 2024 Jun;
11(7):e540-e549.
PMID: 38937027
Early diagnosis is crucial for the successful treatment of primary CNS lymphoma (PCNSL), a rapidly progressing tumour. Suspicion raised on brain MRI must be confirmed by a histopathological diagnosis of...
8.
Pompeo E, Gagliardi F, Medone M, Roncelli F, De Domenico P, Snider S, et al.
J Craniovertebr Junction Spine
. 2023 Oct;
14(3):306-310.
PMID: 37860026
Extraskeletal chondromas (EC) are uncommon, benign cartilaginous tumours. Most common locations are upper and lower extremities. Location in the neck is extremely rare and reported only within the anterior compartment....
9.
Gagliardi F, De Domenico P, Garbin E, Snider S, Mortini P
J Pineal Res
. 2023 Sep;
75(4):e12910.
PMID: 37705383
Pineal region tumors (PTs) represent extremely rare pathologies, characterized by highly heterogeneous histological patterns. Most of the available evidence for Gamma Knife radiosurgical (GKSR) treatment of PTs arises from multimodal...
10.
Spina A, Boari N, Calvanese F, Gagliardi F, Bailo M, Piloni M, et al.
Adv Exp Med Biol
. 2023 Jul;
1405:507-526.
PMID: 37452951
Brain tumors affecting the orbit and orbital tumors affecting the brain are a heterogeneous group of lesions, with histological features, behaviors, diagnostic criteria, and treatments varying from each other. Dermoid...